Skip to content

Molly Gibson

Origination Partner

Molly Gibson is an Origination Partner at Flagship Pioneering, working to found and grow companies at the intersection of biology and machine learning including Generate: Biomedicines, Tessera Therapeutics, and Cobalt Biomedicines (merged into Sana Biotechnology). She currently serves as co-founder and chief innovation officer of Generate Biomedicines. Prior to joining Flagship in 2017, she led computational biology at Kaleido Biosciences.

Molly received a Ph.D. in computational and systems biology from Washington University in Saint Louis in the Center for Genome Sciences, with the support of a National Science Foundation Graduate Research Fellowship. Molly also holds a B.S. in computer science from Truman State University in Missouri.

While at Washington University, she collaborated with St. Louis Children's Hospital to study the effects of early life interventions on development of the preterm infant gut microbiome and health outcomes. She was also a leader in science outreach and education serving as director and board member of the Young Scientist Program leading over 100 active volunteer scientists with the mission of bringing inquiry-based science to disadvantaged K-12 students. At the graduate level, Molly conceived and developed a bioinformatics course that is now standard for all incoming graduate students in biology and biomedical sciences.

Molly’s work has resulted in multiple pending patents and publications, including articles in Science and Nature. She was honored in 2020 in Endpoints News' 20 under 40 list in biopharma.